 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ICP-332 / InnoCare
Efficacy and Safety of a Highly Selective Oral TYK2/JAK1 Inhibitor, ICP-332, in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase II, Randomized, Placebo-Controlled Trial (Room 20B) - Mar 1, 2024 - Abstract #AAD2024AAD_3777;
- |||| ICP-332 / InnoCare
New P2 trial: Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Jan 27, 2023
P2, N=75, Not yet recruiting, Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
- ||| ICP-332 / InnoCare
Trial completion, Trial completion date, Trial primary completion date: A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects (clinicaltrials.gov) - Aug 8, 2022
P1, N=72, Completed, Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Recruiting --> Completed | Trial completion date: Jul 2022 --> Feb 2022 | Trial primary completion date: Jun 2022 --> Jan 2022
- ||| ICP-332 / InnoCare
New P1 trial: A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects (clinicaltrials.gov) - May 31, 2022
P1, N=72, Recruiting, Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.